Eli Lilly and Company (NYSE: LLY) shares are trading lower Tuesday. The stock appears to be moving in reaction to an ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

Sean "Diddy" Combs made an unexpected 9-word statement during the first day of his trial in New York City. The media mogul ...

Lilly plans to break ground Tuesday afternoon on its $4.5 billion Lilly Medicine Foundry in Lebanon. Lilly Chair and CEO Dave ...

Under terms of the deal, Alchemab will lead early Phase I trials for ATLX-1282 in amyotrophic lateral sclerosis, while Lilly ...

Eli Lilly & Co.’s shares dropped in premarket trading after CVS Health Corp. announced a plan to drop its blockbuster ...

Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Lilly Oxford doesn’t need many reminders that, after winning the program’s first state title last season, Hackett’s softball ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...

Eli Lilly & Co.’s shares fell 6% early Thursday after the drugmaker cut its full-year earnings outlook citing research costs ...